Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Kalincik, Tomas ^a   Spelman, Timothy ^b   Trojano, Maria ^c   Duquette, Pierre ^d   Izquierdo, Guillermo ^e   Grammond, Pierre ^f   Lugaresi, Alessandra ^g   Hupperts, Raymond ^h   Cristiano, Edgardo ⁱ   Van Pesch, Vincent ^j   Grand'Maison, Francois ^k   La Spitaleri, Daniele ^l   Rio, Maria Edite ^m   Flechter, Sholmo ⁿ   Oreja Guevara, Celia ^o   Giuliani, Giorgio ^p   Savino, Aldo ^q   Amato, Maria Pia ^r   Petersen, Thor ^s   Fernandez Bolanos, Ricardo ^t   Bergamaschi, Roberto ^u   Iuliano, Gerardo ^v   Boz, Cavit ^w   Lechner Scott, Jeannette ^x   Deri, Norma ^y   Gray, Orla ^z   Verheul, Freek ^aa   Fiol, Marcela ^ab   Barnett, Michael ^ac   Van Munster, Erik ^ad   Santiago, Vetere ^ae   Moore, Fraser ^af   Slee, Mark ^ag   Saladino, Maria Laura ^ah   Alroughani, Raed ^ai   Shaw, Cameron ^aj   Kasa, Krisztian ^ak   Petkovska Boskova, Tatjana ^al   Den Braber Moerland, Leontien ^am   Chapman, Joab ^an   Skromne, Eli ^ao   Herbert, Joseph ^ap   Poehlau, Dieter ^aq   Needham, Merrilee ^ar   Bacile, Elizabeth Alejandra Bacile ^as   Arruda, Walter Oleschko ^at   Paine, Mark ^au   Singhal, Bhim ^av   Vucic, Steve ^aw   Cabrera Gomez, Jose Antonio ^ax   Butzkueven, Helmut ^a,ay   more..

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c UNIVERSITY OF BARI   (Italy)

^d NOTRE DAME HOSPITAL   (Canada)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f Hotel Dieu de Levis Hospital   (Canada)

^g UNIVERSITY OF CHIETI   (Italy)

^h Zuyderland Medical Centre   (Netherlands)

ⁱ HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^j CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^k HÔPITAL CHARLES LEMOYNE   (Canada)

^l AORN San Giuseppe Moscati   (Italy)

^m HOSPITAL DE SÃO JOÃO   (Portugal)

ⁿ ASSAF HAROFEH MEDICAL CENTER   (Israel)

^o HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^p Ospedale di Macerata   (Italy)

^q Servicio de Alergia   (Argentina)

^r UNIVERSITY OF FLORENCE   (Italy)

^s AARHUS UNIVERSITY HOSPITAL   (Denmark)

^t HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^u C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^v Ospedali Riuniti di Salerno   (Italy)

^w KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^x JOHN HUNTER HOSPITAL   (Australia)

^y HOSPITAL JUAN A FERNÁNDEZ   (Argentina)

^z CRAIGAVON AREA HOSPITAL   (United Kingdom)

^aa Groen Hart Ziekenhuis   (Netherlands)

^ab FLENI   (Argentina)

^ac UNIVERSITY OF SYDNEY   (Australia)

^ad JEROEN BOSCH HOSPITAL   (Netherlands)

^ae HIGA Gral   (Argentina)

^af MCGILL UNIVERSITY   (Canada)

^ag FLINDERS UNIVERSITY   (Australia)

^ah INEBA ^*  (Argentina)

^ai AL AMIRI HOSPITAL   (Kuwait)

^aj GEELONG HOSPITAL   (Australia)

^ak Jahn Ferenc Del Pesti korhaz Budapest   (Hungary)

^al Clinic of Neurology Clinical Center   (Macedonia)

^am Francicus Ziekenhuis   (Netherlands)

^an SHEBA MEDICAL CENTER   (Israel)

^ao Hospital Angeles Mexico   (Mexico)

^ap NYU HOSPITAL FOR JOINT DISEASES   (United States)

^aq Kamillus Klinik   (Germany)

^ar ROYAL NORTH SHORE HOSPITAL   (Australia)

^as Instituto de Neurociencias   (Argentina)

^at Hospital Ecoville   (Brazil)

^au ST VINCENT S HOSPITAL   (Australia)

^av BOMBAY HOSPITAL   (India)

^aw WESTMEAD HOSPITAL   (Australia)

^ax CENTRO INTERNACIONAL DE RESTAURACIÓN NEUROLÓGICA CIREN   (Cuba)

^ay MONASH UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BETA INTERFERON;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PROPENSITY SCORE; REGISTER; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; CLINICAL TRIAL; COMPARATIVE STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; REPRODUCIBILITY; STATISTICAL MODEL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; LIKELIHOOD FUNCTIONS; MAGNETIC RESONANCE IMAGING; MALE; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS; PROPENSITY SCORE; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84891613722     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063480     Document Type: Article

References (20)

1. Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, et al. (2006) MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler 12: 769-774. (Pubitemid 46111769)
2. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Di Renzo V (2009) Observational studies: propensity score analysis of non-randomized data. Int MS J 16: 90-97.
3. Rosenbaum PR, Rubin DB (1984) Reducing bias in observational studies using subclassification on the propensity score. Journal of American Statistical Association 79: 516-524.
4. Lunceford JK, Davidian M (2004) Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 23: 2937-2960. (Pubitemid 39200133)
5. Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, et al. (2007) New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 61: 300-306. (Pubitemid 46676729)
6. Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, et al. (2012) Establishing Long-Term Efficacy in Chronic Disease: Use of Recursive Partitioning and Propensity Score Adjustment to Estimate Outcome in MS. PLoS One 6: e22444.
7. Conway DS, Miller DM, O'Brien RG, Cohen JA (2012) Long term benefit of multiple sclerosis treatment: an investigation using a novel data collection technique. Mult Scler.
8. PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352: 1498-1504.
9. Ho DE, Imai K, King G, Stuart EA (2006) Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference. Political Analysis 15: 199-236.
10. Gu XS, Rosenbaum PR (1993) Comparison of Multivariate Matching Methods: Structures, Distances, and Algorithms. J Comput Graph Stat 4: 405-420.
11. King G, Zeng LC (2006) The dangers of extreme counterfactuals. Political Analysis 14: 131-159. (Pubitemid 43444515)
12. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, et al. (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59: 1496-1506. (Pubitemid 35387053)
13. Lublin F, Cofield S, Cutter G, Conwit R, Narayana P, et al. (2013) Randomized study combining interferon & glatiramer acetate in multiple sclerosis. Annals of neurology in press.
14. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, et al. (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380: 1819-1828.
15. Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, et al. (2012) Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 308: 247-256.
16. Prosperini L, Gianni C, Leonardi L, De Giglio L, Borriello G, et al. (2012) Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 18: 64-71.
17. Trojano M, Russo P, Fuiani A, Paolicelli D, Di Monte E, et al. (2006) The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. Mult Scler 12: 578-585. (Pubitemid 46940631)
18. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, et al. (2009) Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 66: 513-520.
19. Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Zimatore GB, et al. (2009) Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment. J Neurol Sci 286: 109-113.
20. Meyniel C, Spelman T, Jokubaitis VG, Trojano M, Izquierdo G, et al. (2012) Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS One 7: e38661.